William E. Holtz

FDA Medical Devices: Important Regulatory Considerations For Companies Seeking To Enter The U.S. Market

FDA Clarifies Policies For Pharmacy Compounders Of GLP-1 Products

FDA To Consider Lifting Restrictions On Numerous Compounded Peptides

Psychedelics And The Executive Order: From Schedule I To Treatment Priority

Digital Health Policy: FDA Relaxes Restrictions Over Wearables And AI Decision Making Tools In Two New 2026 Guidances

FDA Considers Drug Pricing: Leadership Cites Consumer Cost As A Driver For Changes To Biosimilar Recommendations

FDCA: Fifth Circuit End-Run Suggests State Law Private Right Of Action

FDA On The Offense! Targeting Pharmaceutical Company Drug Advertising In Wave Of Enforcement Actions

FDA Calls For Stronger Industry Collaboration On Infant And Child Food Recalls